Aziyo Biologics Presents Clinical Data On CanGaroo Biologic Envelope In Patients Receiving Cardiac Implantable Electronic Devices
Portfolio Pulse from Vandana Singh
Aziyo Biologics Inc (NASDAQ:AZYO) announced that data from the HEAL Study will be presented at the Heart Rhythm Society, comparing the performance of its CanGaroo Envelope with Medtronic Plc's (NYSE:MDT) Tyrx non-biologic envelope and no envelope in patients receiving cardiac implantable electronic devices. The CanGaroo Envelope showed better results in several aspects, and AZYO shares are up 4.72% at $2.22.

May 19, 2023 | 3:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Aziyo Biologics' CanGaroo Envelope outperformed Medtronic's Tyrx non-biologic envelope in the HEAL Study.
The HEAL Study data presentation shows that Aziyo Biologics' CanGaroo Envelope performed better than Medtronic's Tyrx non-biologic envelope in several aspects. This may lead to increased competition for Medtronic in the cardiac implantable electronic devices market and could have a short-term negative impact on its stock price.
CONFIDENCE 90
IMPORTANCE 60
RELEVANCE 80
POSITIVE IMPACT
Aziyo Biologics' CanGaroo Envelope showed better results in the HEAL Study, and its shares are up 4.72% at $2.22.
The HEAL Study data presentation at the Heart Rhythm Society shows that Aziyo Biologics' CanGaroo Envelope performed better than Medtronic's Tyrx non-biologic envelope and no envelope in several aspects. This positive news is likely to boost investor confidence in the company and its product, leading to a short-term increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100